Collegium Pharmaceutical(COLL) - 2025 Q2 - Quarterly Results

– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of$ 32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of$ 745 to $760 Million and Adjusted EBITDA Guidance in the Range of$ 440 to $455 Million ...